On March 26, 2026, the FDA approved Awiqli® (insulin icodec abae) from Novo Nordisk – the first once‑weekly basal insulin for adults with type 2 diabetes. This milestone represents a meaningful shift in basal insulin therapy. Awiqli® provides continuous basal insulin coverage with a single weekly injection, potentially reducing treatment burden for patients who require insulin as their disease progresses. The pricing has not yet been announced.
As the diabetes landscape continues to evolve – alongside GLP‑1s, biosimilars, and delivery innovations – this approval underscores the importance of thoughtful formulary evaluation and patient‑centric benefit design. Awiqli® will be excluded at launch on the ProAct Advantage Formulary pending completion of the formulary review process.
